Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
Date:9/14/2011

SAN FRANCISCO, Sept. 14, 2011 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2011 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Tuesday, September 20, 2011 at 10:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until October 25, 2011.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Fr
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
2. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
3. Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
5. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
6. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
7. Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
10. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 Nonin Medical, ... that President and Chief Operating Officer Steve Bucholz ... Isaacson is expanding his role as Chief Executive ... role as Chief Technology Officer. Operations will transition to ... " Steve Bucholz has been instrumental to Nonin ...
(Date:4/17/2015)... WOONSOCKET, R.I , April 17, 2015 ... holding a conference call on Friday, May 1, 2015, ... discuss its first quarter financial results. An ... simultaneously through the Investor Relations portion of the CVS ... webcast, visit http://investors.cvshealth.com . This webcast will be ...
(Date:4/17/2015)... ASSESS shows   plasma circulating ... viable alternative to tumour biopsy   IGNITE ... advanced NSCLC   AstraZeneca today presented results from ... DNA (ctDNA) testing for epidermal growth factor receptor (EGFR) mutation ... cancer (NSCLC) in clinical practice. [ 1 ] ...
Breaking Medicine Technology:Nonin Medical's Philip Isaacson Expands CEO Role; President and COO Steve Bucholz to Retire May 1 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4
... Makes Rapid Recovery after Procedure Utilizing IlluminOss(TM) Photodynamic ... Medical today announced that one of the leading ... performed the first case in the world utilizing ... orthopedic surgery. The IlluminOss Photodynamic Bone Stabilization ...
... Feb. 24 BioTrends is pleased to announce the fielding of ... (R) . Takeda Pharmaceutical Company Limited announced that they ... febuxostat) on February 13, 2009. Uloric (R) ... and represents the first product for gout that has been approved ...
Cached Medicine Technology:IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile 2IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile 3
(Date:4/18/2015)... (PRWEB) April 18, 2015 "I recognized ... stretchers in healthcare facilities," said an inventor from Cincinnati, ... storage system." , He developed the Slyde Door to ... used in healthcare facilities. It provides convenient storage space ... are more stretchers available for patients. , This ...
(Date:4/18/2015)... has released a new blog post explaining how to ... Clients can review important auto insurance quotes online, by ... advantages for clients who need affordable financial security for ... coverage for their vehicles can purchase a policy at ... agencies offer important discounts and drivers can learn more ...
(Date:4/18/2015)... April 18, 2015 Patients who undergo ... developing mesothelioma later in life, but the disease is ... that is unrelated to radiation. Surviving Mesothelioma has just ... website. Click here to read it now. ... the cases of 45 patients who had both a ...
(Date:4/18/2015)... than 2000 styles of newly designed prom dresses are ... carrying celebrity inspired special occasion dresses. With the prom ... for their prom. For those who are still looking ... be an ideal choice. , "We have by ... the most loved styles seen at this years major ...
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as part ... latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... In a turbulent world, people may find themselves in dangerous ... their first move, but some situations can be avoided if ...
Breaking Medicine News(10 mins):Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:A Personal Safety Application was Featured on NewsWatch Television 2
... days after trauma, developers say , WEDNESDAY, Sept. 12 ... monitor blood flow through the brain in real time, ... head injuries. , Brain trauma is a top killer ... suffer brain injuries annually, according to the U.S. Centers ...
... Scientists have identified a distinct subpopulation of cancer stem ... deadly human pancreatic cancer. The research, published by Cell ... Stem Cell, provides insight into the role of CSCs ... directions for development of more effective therapeutics. , Pancreatic ...
... - Treatment in private doctors, offices with FDA-approved medication could, ... ... killers-, RICHMOND, Va., Sept. 12 ... released by the Substance Abuse and,Mental Health Services Administration (SAMHSA), shows that ...
... EXTON, Pa., Sept. 12 Kensey Nash Corporation,(Nasdaq: ... earnings results,for its first quarter ended September 30, 2007 ... Joe Kaufmann, President and CEO, will be hosting ... 2007 at 9:00 A.M.,Eastern Time. To participate in ...
... against macular degeneration, study finds , WEDNESDAY, Sept. 12 ... the yellow plant pigments lutein and zeaxanthin may have ... a leading cause of irreversible blindness among the elderly. ... supported by the U.S. government, looked at more than ...
... 12, 2007 Rice University chemists have discovered a way ... onto tiny gold spheres. The result is a tiny ball, ... with the drug. , Paclitaxel, which is sold under the ... their inner works. , "Paclitaxel is one of the most ...
Cached Medicine News:Health News:Imaging Software Helps Track, Treat Injured Brains 2Health News:Cancer stem cell subpopulation drives metastasis of human pancreatic cancer 2Health News:Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults 2Health News:Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults 3Health News:Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults 4Health News:Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults 5Health News:Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference 2Health News:Taxol bristle ball: a wrench in the works for cancer 2
... double spot test is a rapid, ... antibodies to T. cruzi in human ... samples. This test is intended primarily ... reactive samples should be confirmed by ...
... is intended for the immunochromatographic, qualitative ... samples.,Smart Strip Gonorrhea is based on ... the determination of gonorrhea antigen in ... urinary system as an aid in ...
Inquire...
For the rapid determination of human chorionic gonadotropin (hCG) in urine and serum. The test strip is used to obtain a visual qualitative result....
Medicine Products: